KPV
Overview
Mechanisms
Evidence
[regulatory]US status shifting (2026): KPV was removed from FDA Category 2 (Feb 2026) and is on the FDA PCAC 503A agenda for July 23 2026 — FDA’s evaluated use is wound healing & inflammatory conditions (aligns with its α-MSH-derived anti-inflammatory / cytokine-modulation profile). Advisory/non-binding; not FDA-approved. — SOURCE-fda-pcac-503a-peptide-review-2026